The 5th Neuropsychiatry Symposium of the European Institute of Health care was devoted to neuropsychopharmacology. As in previous meetings, we sought to choose topics that bridge the gap between basic neuroscience and the clinical fields of neurology and psychiatry. Consequently, the pro ceedings published in this supplement cover a lot of ground. Late breaking data on various neuromodulator and neurotransmitter systems and their implications for the treatment of a number of disorders are reviewed. Jean Charles Schwartz and colleagues set the stage with their paper on constitu tive receptor activity, using the histamine H3-receptor to illustrate the point. The role of neuropeptides and neurotrophins in psychiatric disorders is then reviewed by Florian Holsboer, while Bill Deakin elucidates the role of sero tonin, discovered 50 years ago in the brain, in select psychiatric syndromes. New pharmacological developments in the treatment of migraine, Parkin son's disease and schizophrenia are then presented by Hans Christoph Diener, Eduardo Tolosa and Wolfgang Fleischhacker. In the end David Nutt and colleagues provide future directions in substance dependence research, linking the role of various transmitter systems with findings from neu roimaging studies. In summary, there is no doubt that progress in the field of neuropsychopharmacology is exciting and the prospects of true advances in the treatment of brain disorders are very promising.
What people are saying - Write a review
We haven't found any reviews in the usual places.
the example of the histamine H3 receptor
The role of peptides in treatment of psychiatric disorders
Pharmacological approaches to migraine
Advances in the pharmacological management of Parkinson disease
two contrasting disorders of SHT function
Future directions in substance dependence research
New developments in the pharmacotherapy of schizophrenia
Other editions - View all
5-HT function acid acute migraine acute treatment addiction almotriptan antidepressant antipsychotic drugs anxiety BDNF behavioral binding brain cells Cephalalgia cerebral ciproxifan Clin clinical trials clozapine cocaine cognitive compared constitutive activity cortex cortisol CRHR1 decreased dementia depression Diener HC dopamine dopaminergic dosages dose double-blind dyskinesias efficacy eletriptan flunarizine frovatriptan H3 receptor hallucinations hippocampus histamine Holsboer F hormone imetit increased induced inhibition inhibitors inverse agonism inverse agonists levodopa ligands membranes metoprolol migraine migraine attacks migraine prophylaxis monotherapy Morisset motor naratriptan Neurol neuroleptics Neurology neuropeptides Neurosci neurotransmitter neutral antagonist Nutt olanzapine oral sumatriptan pain free Parkinson's disease PD patients peptide personality disorder Pharmacol pharmacological placebo prophylactic prophylaxis prophylaxis of migraine propranolol protein proxyfan Psychiatry psychosis quetiapine rats receptor antagonist release response risperidone Rizatriptan S]GTPy[S schizophrenia serotonin side effects sleep stress Study Group substance sumatriptan symptoms Tfelt-Hansen therapeutic therapy tion Tolosa treated treatment of migraine triptans vasopressin zolmitriptan